Open AccessIntracoronary reopro during percutaneous coronary intervention in acute and stable patient can influence stent thrombosis formation (IRPASST) study
Author(s) -
Mohammed Balghith,
Ali Alghamdi,
El Harif Zain,
Ahmed Alsaileek
Publication year - 2013
Publication title -
heart views
Language(s) - English
Resource type - Journals
eISSN - 0976-5123
pISSN - 1995-705X
DOI - 10.4103/1995-705x.115498
Subject(s) - medicine , abciximab , percutaneous coronary intervention , mace , myocardial infarction , bolus (digestion) , conventional pci , stent , angioplasty , unstable angina , tirofiban , cardiology , anesthesia
In patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty, abciximab reduces major adverse cardiac events (MACE). Most clinical trials have studied mainly intravenous administration. Intracoronary (IC) bolus application of abciximab causes very high local drug concentrations and may be more effective in reducing acute and sub-acute stent thrombosis (ST). We studied whether IC bolus administration of abciximab is associated with a reduced ST and target vessels revascularization (TVR); therefore, less MACE rate compared with the standard intravenous IV bolus and infusion application.